Compare TWIN & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWIN | SENS |
|---|---|---|
| Founded | 1918 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Industrial Machinery/Components |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.9M | 301.2M |
| IPO Year | 1994 | 2014 |
| Metric | TWIN | SENS |
|---|---|---|
| Price | $24.85 | $8.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $18.38 |
| AVG Volume (30 Days) | 77.6K | ★ 694.4K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.76 | N/A |
| Revenue | ★ $340,738,000.00 | $16,389,000.00 |
| Revenue This Year | $10.79 | $74.15 |
| Revenue Next Year | $8.43 | $58.60 |
| P/E Ratio | $14.18 | ★ N/A |
| Revenue Growth | 15.45 | ★ 19.85 |
| 52 Week Low | $8.50 | $0.41 |
| 52 Week High | $25.30 | $8.88 |
| Indicator | TWIN | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 60.09 | 82.13 |
| Support Level | $14.76 | $5.20 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.98 | 0.55 |
| MACD | 0.06 | 0.34 |
| Stochastic Oscillator | 80.74 | 98.50 |
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.